[New strategy for diagnosis and treatment of acute promyelocytic leukemia with t (15;17)].
All-trans retinoic acid (ATRA)-therapy against acute promyelocytic leukemia (APL) is epoch-making in the sense of the first success in both tumor-differentiation therapy and molecule-targeted therapy. Kouseishou APL-study group performed three clinical studies to refractory APL with ATRA from 1990 to 1993. Complete remission (CR) was obtained in 82%, 88% and 78% of 22, 41 and 46 patients, respectively. Molecular diagnosis of the t (15;17) translocation was possible using Southern blot analysis and reverse transcriptase polymerase chain reaction (RT-PCR).
Kubo
K
K
Department of Internal Medicine, Nagoya University Branch Hospital.
Naoe
T
T
Fukutani
H
H
Ohno
R
R
D002884:Chromosomes, Human, Pair 15; D002886:Chromosomes, Human, Pair 17; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D012074:Remission Induction; D014178:Translocation, Genetic; D014212:Tretinoin / Q000627:therapeutic use*
D014212:Tretinoin